Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies
DIABETES OBESITY & METABOLISM (2019)
期刊
DIABETES OBESITY & METABOLISM
卷 21, 期 2, 页码 210-217出版社
WILEY
关键词
作者
我是这篇论文的作者
推荐
Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis
Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, Anoop Misra, Zachary Bloomgarden
JOURNAL OF DIABETES (2023)
Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Angel Martinez-Gonzalez., Jordi Salas-Salvado, Dolores Corella, Albert Goday, J. Alfredo Martinez, Angel M. Alonso-Gomez, Olga Fernandez-Barcelo, Jesus Vioque, Dora Romaguera, Jose Lopez-Miranda, Ramon Estruch, Francisco J. Tinahones, Jose Lapetra, Lluis Serra-Majema, Blanca Riquelme-Gallegop, Vicente Martin-Sanchez, Xavier Pinto, Miguel Delgado-Rodriguez, Pilar Matia, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefania Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Angel Munoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Munoz-Bravoaf, Salvador Miralles-Gisbert, Marian Martin, Antonio Garcia-Rios, Sara Castro-Barquero, Jose Carlos Fernandez-Garcia, Jose Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutierrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Diez-Espino, Nancy Babio, Montse Fito, Josep A. Tur
BIOMEDICINE & PHARMACOTHERAPY (2023)
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Mariusz Dabrowski
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, Keming Yang, Joshua Brown, Stephen Anton, Yonghui Wu, Adam Bress, William T. Donahoo, Steven T. DeKosky, Jiang Bian, Jingchuan Guo
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)
Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies
Ting-Wei Lee, Ting-I. Lee, Yung-Kuo Lin, Yao-Chang Chen, Yu-Hsun Kao, Yi-Jen Chen
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials
Aihua Wang, Huilin Tang, Ning Zhang, Xin Feng
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
Christina E. DeRemer, Scott M. Vouri, Jingchuan Guo, William T. Donahoo, Almut G. Winterstein, Hui Shao
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)
A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
Insiya B. Poonawalla, Andy T. Bowe, Michael C. Tindal, Yunus A. Meah, Phil Schwab
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis
Ghadeer K. Dawwas, James H. Flory, Sean Hennessy, Charles E. Leonard, James D. Lewis
DIABETES CARE (2022)
Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
Sanbao Chai, Fengqi Liu, Zhirong Yang, Shuqing Yu, Zuoxiang Liu, Qingqing Yang, Feng Sun
FRONTIERS IN PHARMACOLOGY (2022)
Addressing screams for evidence on renoprotection by GLP-1 receptor agonists
Takayoshi Sasako, Toshimasa Yamauchi
KIDNEY INTERNATIONAL (2022)
On the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects?
Lucia Scisciola, Fabiola Olivieri, Concetta Ambrosino, Michelangela Barbieri, Maria Rosaria Rizzo, Giuseppe Paolisso
AGEING RESEARCH REVIEWS (2023)
SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
Zheer Kejlberg Al-Mashhadi, Rikke Viggers, Jakob Starup-Linde, Peter Vestergaard, Soren Gregersen
FRONTIERS IN ENDOCRINOLOGY (2022)
Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach
Meir Schechter, Matan Fischer, Ofri Mosenzon
DIABETES OBESITY & METABOLISM (2022)
Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study
Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju-Young Shin, Young Min Cho
DIABETES OBESITY & METABOLISM (2023)
Efficacy of semaglutide versus liraglutide in clinical practice
E. Goncalves, D. S. Bell
DIABETES & METABOLISM (2020)
Stroke in the patient with diabetes (Part 2) ? Prevention and the effects of glucose lowering therapies
David S. H. Bell, Edison Goncalves
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Stroke in the patient with diabetes (part 1) ? Epidemiology, etiology, therapy and prognosis
David S. H. Bell, Edison Goncalves
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin
David S. H. Bell, Edison Goncalves
DIABETES THERAPY (2020)
Diabetogenic effects of cardioprotective drugs
David S. H. Bell, Edison Goncalves
DIABETES OBESITY & METABOLISM (2021)
Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy
Terri Jerkins, David S. H. Bell
DIABETES THERAPY (2021)
Alcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked
David S. H. Bell, Edison Goncalves
DIABETES THERAPY (2021)
Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes
David S. H. Bell
DIABETES OBESITY & METABOLISM (2022)
Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient
David S. H. Bell, Terri Jerkins
DIABETES THERAPY (2022)
Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy
David S. H. Bell
JOURNAL OF DIABETES RESEARCH (2022)
Diabetic Mononeuropathies and Diabetic Amyotrophy
David S. H. Bell
DIABETES THERAPY (2022)
Heart failure and diabetes: Clinical significance and epidemiology of this two-way association
Terri Jerkins, Janet B. B. McGill, David S. H. Bell
DIABETES OBESITY & METABOLISM (2023)
Detecting and treating the protean manifestations of diabetic autonomic neuropathy
David S. H. Bell
DIABETES OBESITY & METABOLISM (2023)
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome
David S. H. Bell, Terri Jerkins
DIABETES OBESITY & METABOLISM (2023)
Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes
David S. H. Bell, Janet B. B. McGill, Terri Jerkins
DIABETES OBESITY & METABOLISM (2023)